Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences develops clinical-stage precision medicines that target Fibroblast Growth Factor Receptor (FGFR) biology. News about TYRA commonly centers on its SNÅP drug-design platform, oral dabogratinib as an FGFR3-selective inhibitor, and pipeline programs in targeted oncology and genetically defined conditions.
Recurring updates include financial results, scientific conference presentations, clinical-study progress in urologic cancers, achondroplasia, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and governance or leadership changes. Company announcements also cover investor-conference participation and program descriptions for TYRA-430 and TYRA-200.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm specializing in precision medicines for FGFR biology, will participate in several investor conferences. On May 28-29, 2024, CEO Todd Harris will join a fireside chat at TD Cowen's Oncology Innovation Summit. The company will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 5-6, 2024. Additionally, Harris will present on June 12, 2024, at the Goldman Sachs Global Healthcare Conference, with further investor meetings scheduled. Webcasts of these presentations will be available on Tyra's Investor page.
Tyra Biosciences, a clinical-stage biotechnology company, reported financial results for Q1 2024, with $382.5 million in cash and marketable securities. Recent highlights include progress on TYRA-300 in oncology and achondroplasia, new board appointments, and completion of a $200M private placement financing. The company continues to advance its pipeline and expects to report SURF301 Phase 1 initial results in 2H24.
Tyra Biosciences, a clinical-stage biotech company, appointed Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, replacing Isan Chen, M.D. Both new directors bring extensive expertise in FGFR3 biology and oncology. Dr. Moran has a background in clinical trials and product development, while Dr. Rothenberg has experience in clinical care and drug development. The changes aim to advance the company's precision medicine candidates, particularly TYRA-300 for skeletal dysplasias and oncology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.